Anavex Life Sciences Corp. (AVXL)
$9.15
Insights on Anavex Life Sciences Corp.
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 41.8% return, outperforming this stock by 28.8%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 137.5% return, outperforming this stock by 12.1%
Performance
- $8.92$10.14$9.15
2.51%
Downside
Day's Volatility :12.03%
Upside
9.76%
- $7.36$15.24$9.15
19.56%
Downside
52 Weeks Volatility :51.71%
Upside
39.96%
Returns
| Period | Anavex Life Sciences Corp. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 2.9% | 5.1% | -0.2% |
6 Months | 6.57% | -5.5% | -1.5% |
1 Year | 12.96% | 3.9% | -1.7% |
3 Years | 125.37% | 27.0% | 20.6% |
Highlights
Market Capitalization | 750.9M |
Book Value | $1.81 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.68 |
PEG Ratio | 0.0 |
Wall Street Target Price | 47.75 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -21.19% |
Return On Equity TTM | -35.47% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -0.68 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.7 |
EPS Estimate Next Year | -0.63 |
EPS Estimate Current Quarter | -0.19 |
EPS Estimate Next Quarter | -0.19 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 421.86%
Technicals Summary
Sell
Neutral
Buy
Anavex Life Sciences Corp. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Anavex Life Sciences Corp. | -1.28% | 6.57% | 12.96% | 125.37% | 124.26% |
 Moderna, Inc. | -5.8% | -25.37% | -3.05% | 105.16% | 562.58% |
 Regeneron Pharmaceuticals, Inc. | -0.38% | 0.57% | 30.59% | 23.1% | 139.38% |
 Novo Nordisk A/s | -6.71% | 21.75% | 41.76% | 137.45% | 252.55% |
 Seagen, Inc. | -1.72% | 49.08% | 41.0% | 25.43% | 194.5% |
 Vertex Pharmaceuticals Incorporated | -4.66% | 6.21% | 30.93% | 21.64% | 124.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Anavex Life Sciences Corp. | NA | NA | 0.0 | -0.7 | -0.35 | -0.21 | 0.0 | 1.81 |
Moderna, Inc. | 10.82 | 10.82 | 0.0 | -1.63 | 0.27 | 0.12 | 0.0 | 49.12 |
Regeneron Pharmaceuticals, Inc. | 20.46 | 20.46 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
Novo Nordisk A/s | 44.45 | 44.45 | 2.03 | 4.98 | 83.5 | 0.23 | 0.01 | 4.44 |
Seagen, Inc. | NA | NA | 18.53 | -2.89 | -0.23 | -0.12 | 0.0 | 14.54 |
Vertex Pharmaceuticals Incorporated | 25.51 | 25.51 | 0.41 | 14.57 | 0.26 | 0.17 | 0.0 | 56.05 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Anavex Life Sciences Corp. | Buy | $750.9M | 124.26% | NA | 0.0% |
Moderna, Inc. | Buy | $47.6B | 562.58% | 10.82 | 31.77% |
Regeneron Pharmaceuticals, Inc. | Buy | $82.3B | 139.38% | 20.46 | 33.81% |
Novo Nordisk A/s | Buy | $1.9T | 252.55% | 44.45 | 32.47% |
Seagen, Inc. | Hold | $36.5B | 194.5% | NA | -31.55% |
Vertex Pharmaceuticals Incorporated | Buy | $85.1B | 124.53% | 25.51 | 35.4% |
Institutional Holdings
State Street Corporation
7.02%BlackRock Inc
6.90%Vanguard Group Inc
5.16%Geode Capital Management, LLC
1.74%Northern Trust Corp
0.90%Goldman Sachs Group Inc
0.83%
Corporate Announcements
Anavex Life Sciences Corp. Earnings
Anavex Life Sciences Corp.’s price-to-earnings ratio stands at None
Read More
Company Information
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
Organization | Anavex Life Sciences Corp. |
Employees | 38 |
CEO | Dr. Christopher U. Missling M.B.A., M.S., Ph.D. |
Industry | Health Technology |
Discover More
Smart For Life Inc
$1.14
-2.56%
Paysign, Inc.
$2.64
+2.33%
Novavax, Inc.
$7.47
-2.86%
Silvercrest Metals Inc
$6.27
-2.18%
Fidelity U.s. Multifactor Etf
$25.43
-0.04%
Proshares Ultrapro Dow30 Etf
$57.69
+0.47%
Invesco Dynamic Large Cap Va
$45.62
-0.02%
Blackrock Municipal Income Quality Trust
$11.15
+0.18%
Tupperware Brands Corporation
$0.86
+0.83%